Annual report
4978.TEDINET S100YLVF
Period2025-04-01 → 2026-03-31
Filed2026-06-26
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 133
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.2bn | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥3.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥2.4bn | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.0bn | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.2bn | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Operating income | −¥860m | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | −¥130m | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | −¥581m | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥45m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥40m | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥120m | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥507m | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥587m | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥45m | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥592m | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥103m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥31m | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥305m | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥575m | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥592m | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥103m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥9.7bn | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥9.7bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥9.1bn | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥8.4bn | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥8.1bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥806m | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥686m | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥8.8bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥9.0bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥8.3bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥7.6bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥7.3bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.6bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.8bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.6bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.8bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.9bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.9bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥2.6bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥384m | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥6m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥11m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥141m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥246m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥58m | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥796m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥404m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.1bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.1bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥680m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥544m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥483m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥2.4bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-6.25 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥1.11 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-0.37 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.62 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-7.57 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥93.09 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥94.89 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥93.41 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥89.01 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥88.11 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 91.7% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.8% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 90.7% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.5% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 1.2% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| Employees | 101 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 99 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 96 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 92 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 98 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥624m | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥960m | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥941m | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.6bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.3bn | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | −¥609m | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | −¥401m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | −¥331m | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥285m | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥62m | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥112m | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥382m | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥339m | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥304m | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | −¥341m | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | −¥306m | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | −¥205m | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | −¥297m | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | −¥541m | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥9.2bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥9.0bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥8.8bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥8.4bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥8.2bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥462m | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥368m | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥8.7bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥8.6bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥8.4bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥7.9bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥7.5bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.1bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.3bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-3.6 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.29 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-2.4 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.52 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-7.13 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥91.6 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥91.29 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥94.05 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥92.42 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥91.73 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 95.0% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 95.9% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 95.3% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.8% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.1% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 95,147,891 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 94,802,891 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 89,013,591 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 85,141,191 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 82,270,891 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 30 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 28 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 26 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 28 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 31 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 50
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2025-04-01 → 2026-03-31 | ¥7m |
| Reconciling Itemsreconciling | depreciation | 2025-04-01 → 2026-03-31 | ¥4m |
| Reconciling Itemsreconciling | segment assets | at 2026-03-31 | ¥8.7bn |
| Reconciling Itemsreconciling | segment ordinary income | 2025-04-01 → 2026-03-31 | −¥634m |
| Medical Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥55m |
| Medical Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥46m |
| Medical Businessreportable segment | employees | at 2026-03-31 | 7 pure |
| Medical Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥281m |
| Medical Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥281m |
| Medical Businessreportable segment | segment assets | at 2026-03-31 | ¥282m |
| Medical Businessreportable segment | segment ordinary income | 2025-04-01 → 2026-03-31 | −¥44m |
| Research Support Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥37m |
| Research Support Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥22m |
| Research Support Businessreportable segment | employees | at 2026-03-31 | 70 pure |
| Research Support Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥2.0bn |
| Research Support Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥2.0bn |
| Research Support Businessreportable segment | segment assets | at 2026-03-31 | ¥632m |
| Research Support Businessreportable segment | segment ordinary income | 2025-04-01 → 2026-03-31 | ¥97m |
| —segment total | capex | 2025-04-01 → 2026-03-31 | ¥92m |
| —segment total | depreciation | 2025-04-01 → 2026-03-31 | ¥69m |
| —segment total | employees | at 2026-03-31 | 77 pure |
| —segment total | revenue | 2025-04-01 → 2026-03-31 | ¥2.2bn |
| —segment total | revenue external | 2025-04-01 → 2026-03-31 | ¥2.2bn |
| —segment total | segment assets | at 2026-03-31 | ¥914m |
| —segment total | segment ordinary income | 2025-04-01 → 2026-03-31 | ¥53m |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥5m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥3m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥8.7bn |
| Reconciling Itemsreconciling | segment ordinary income | 2024-04-01 → 2025-03-31 | −¥735m |
| Medical Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥76m |
| Medical Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥25m |
| Medical Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥564m |
| Medical Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥564m |
| Medical Businessreportable segment | segment assets | at 2025-03-31 | ¥363m |
| Medical Businessreportable segment | segment ordinary income | 2024-04-01 → 2025-03-31 | ¥159m |
| Research Support Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥16m |
| Research Support Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥20m |
| Research Support Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥2.4bn |
| Research Support Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥2.4bn |
| Research Support Businessreportable segment | segment assets | at 2025-03-31 | ¥646m |
| Research Support Businessreportable segment | segment ordinary income | 2024-04-01 → 2025-03-31 | ¥621m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥91m |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥45m |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥3.0bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥3.0bn |
| —segment total | segment assets | at 2025-03-31 | ¥1.0bn |
| —segment total | segment ordinary income | 2024-04-01 → 2025-03-31 | ¥780m |
| Medical Businessreportable segment | employees | at 2026-03-31 | 7 pure |
| Research Support Businessreportable segment | employees | at 2026-03-31 | 16 pure |
| —segment total | employees | at 2026-03-31 | 23 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,391
| Item | Context | Value | Unit |
|---|---|---|---|
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 49780 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社リプロセル | |
| Filer name in english | FilingDateInstant | ReproCELL Incorporated | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第三号様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Current fiscal year start date | FilingDateInstant | 2025-04-01 | |
| Current period end date | FilingDateInstant | 2026-03-31 | |
| Type of current period | FilingDateInstant | FY | |
| Current fiscal year end date | FilingDateInstant | 2026-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2024-04-01 | |
| Comparative period end date | FilingDateInstant | 2025-03-31 | |
| Previous fiscal year end date | FilingDateInstant | 2025-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Business results of reporting company (text) | FilingDateInstant | Text · Plus | |
| Company history (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Overview of affiliated entities (text) | FilingDateInstant | Text · Plus | |
| Business policy business environment issues to address etc (text) | FilingDateInstant | Text · Plus | |
| Disclosure of sustainability related financial information (text) | FilingDateInstant | Text · Plus | |
| Governance (text) | FilingDateInstant | Text · Plus | |
| Reference to other information governance | FilingDateInstant | Text · Plus | |
| Strategy (text) | FilingDateInstant | Text · Plus | |
| Policy on development of human resources and internal environment strategy (text) | FilingDateInstant | Text · Plus | |
| Risk management (text) | FilingDateInstant | Text · Plus | |
| Reference to other information risk management | FilingDateInstant | Text · Plus | |
| Reference to other information2 risk management | FilingDateInstant | Text · Plus | |
| Metrics and targets (text) | FilingDateInstant | Text · Plus | |
| Description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics metrics and targets (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Material matters relating to going concern etc business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts (text) | FilingDateInstant | Text · Plus | |
| Research and development activities (text) | FilingDateInstant | Text · Plus | |
| Overview of capital expenditures etc (text) | FilingDateInstant | Text · Plus | |
| Major facilities (text) | FilingDateInstant | Text · Plus | |
| Planned additions retirements etc of facilities (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |